Emmaus Life Sciences, Inc. (EMMA)

Market Cap	4.55M
Revenue (ttm)	29.60M
Net Income (ttm)	-3.73M
Shares Out	63.87M
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	1.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,453
Open	0.0713
Previous Close	0.1030
Day's Range	0.0713 - 0.0713
52-Week Range	0.0510 - 0.2800
Beta	1.67
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2019

About EMMA

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company’s lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its pipeline products include ELS001/ELS007, a pharmaceutical grade L-glutamine, which has completed phase 3 clinical trial to treat sickle cell ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 55
• Stock Exchange: OTCMKTS
• Ticker Symbol: EMMA

Financial Performance

In 2023, EMMA's revenue was $29.60 million, an increase of 60.94% compared to the previous year's $18.39 million. Losses were -$3.73 million, -65.06% less than in 2022.